Disease volumes as a marker for patient response in malignant pleural mesothelioma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 999-1005

  Labby, Z E ^a   Nowak, A K ^b,c   Dignam, J J ^a   Straus, C ^a   Kindler, H L ^a   Armato, S G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chest CT; Malignant pleural mesothelioma; Therapy response assessment

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PEMETREXED;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DECORTICATION; DRUG RESPONSE; DYSPNEA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; PROGNOSIS; SEX; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX PAIN; THROMBOCYTE COUNT; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 84875609758     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds535     Document Type: Article

References (37)

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207-214.
2. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
3. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006; 6(5): 409-414.
4. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24: 3245-3251.
5. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42(8): 1031-1039.
6. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15(2): 257-260.
7. Oxnard GR, Armato SG, III, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 2006; 52 (2): 141-148.
8. Labby ZE, Armato SG, III, Kindler HL, Dignam JJ, Hasani AA, Nowak AK. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7(11): 1728-1734.
9. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques-initial observations. Radiology 2002; 225(2): 416-419.
10. Boone JM. Radiological interpretation 2020: toward quantitative image assessment. Med Phys 2007; 34(11): 4173-4179.
11. Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer 2011; 105 (5): 682-686.
12. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BWS, Byrne MJ et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011; 17(5): 1181-1189.
13. Lee HY, Hyun SH, Lee KS et al. Volume-based parameter of (18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010; 17(10): 2787-2794.
14. Plathow C, Klopp M, Thieke C et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 2008; 18: 1635-1643.
15. Francis RJ, Byrne MJ, van der Schaaf AA et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-1458.
16. Veit-Haibach P, Schaefer NG, Steinert HC et al. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010; 67(3): 311-317.
17. Frauenfelder T, Tutic M, Weder W et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 2011; 38(1): 162-168.
18. Liu F, Zhao B, Krug LM et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010; 5(6): 879-884.
19. Boucek JA, Francis RJ, Jones CG et al. Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study. Phys Med Biol 2008; 53(16): 4213-4230.
20. Corson N, Sensakovic WF, Straus C et al. Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans. Med Phys 2011; 38(2): 942-947.
21. Flores RM, Zakowski M, Venkatraman E et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2: 957-965.
22. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113(3): 723-731.
23. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152.
24. Edwards JG, Abrams KR, Leverment JN et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 731-735.
25. Francart J, Vaes E, Henrard S et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009; 45: 2304-2311.
26. Nowak AK, Francis RJ, Phillips MJ et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010; 16(8): 2409-2417.
27. Sensakovic WF, Armato SG, III, Straus C et al. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys 2011; 38(1): 238-244.
28. Herman GT, Zheng J, Bucholtz CA. Shape-based interpolation. IEEE Comput Grap Appl 1992; 12(3): 69-79.
29. Beare R, Lehmann G. The watershed transform in ITK-discussion and new developments. Insight J 2006. http://hdl.handle.net/1926/202.
30. Sensakovic WF, Starkey A, Roberts RY et al. Discrete-space versus continuousspace lesion boundary and area definitions. Med Phys 2008; 35(9): 4070-4078.
31. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd edition. New York, NY: Springer 2010.
32. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34(2): 187-220.
33. Zhou M. Understanding the Cox regression models with time-change covariates. Am Stat 2001; 55: 153-155.
34. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and crossvalidation. Am Stat 1983; 37(1): 36-48.
35. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61(1): 92-105.
36. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2011.
37. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998; 115(2): 310-317.